Isobe N, Uozumi T, Kurisu K, Kawamoto K
Department of Neurosurgery, Hiroshima University School of Medicine, Japan.
Anticancer Res. 1996 Jan-Feb;16(1):71-6.
Anti-angiogenic agents were be clinically useful for the therapy of solid tumors, as the growth and proliferation of tumors require neovascularization. Previous reports have been made on the antitumor effect of TNP-470, an angiogenic inhibitor, on medulloblastomas implanted subcutaneously into nude mice. The present study was undertaken for the purpose of investigating possible antitumor effects on two model subcutaneous and intracranial tumors transplanted into rats. 9-L gliosarcomas were transplanted into the left femoral region subcutaneously and the left frontal region of Fisher 344 female rats, and the TNP-470 was then administered subcutaneously. The rats were divided into two treatment groups and a control group. TNP-470 resulted in dose-dependent inhibition of 9-L gliosarcoma growth and also prolonged survival in treatment groups. Therefore TNP-470 was considered to be effective for the treatment of malignant brain tumors, although it caused dose-dependent decreases in body weight.
抗血管生成剂在实体瘤治疗中具有临床应用价值，因为肿瘤的生长和增殖需要新血管形成。此前已有关于血管生成抑制剂TNP-470对皮下接种于裸鼠的髓母细胞瘤的抗肿瘤作用的报道。本研究旨在探究TNP-470对移植到大鼠体内的两种皮下和颅内肿瘤模型可能产生的抗肿瘤作用。将9-L胶质肉瘤皮下移植到Fisher 344雌性大鼠的左大腿区域和左额叶区域，然后皮下给予TNP-470。大鼠被分为两个治疗组和一个对照组。TNP-470导致9-L胶质肉瘤生长受到剂量依赖性抑制，并且延长了治疗组大鼠的生存期。因此，尽管TNP-470会导致体重出现剂量依赖性下降，但它被认为对恶性脑肿瘤的治疗有效。
